Headquartered in Vancouver, British Columbia, AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that their partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. They partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. AbCellera grew out of the idea that single-cell microfluidics and next-generation technologies can radically change how they discover drugs. Their multidisciplinary team of cell biologists, biochemists, engineers, data scientists, machine learning experts, and business professionals is working on some of the toughest areas of disease. They push the limits of antibody discovery to help partners tackle the world’s most urgent medical challenges. Their Partners: igm Biosciences Inc., Lilly, Gilead, Denali, Bill & Melinda Gates foundation, Novartis, Autolus, gsk, teva, Sanofi, Pfizer, Kodiak, Merck, Ablynx and Lyell.
Legal Name
:
AbCellera Biologics, Inc.
Headquarters
:
Vancouver, Washington, United States
Founding Date
:
2012
No. of Employees
:
151 to 250
Core Team
3.
Co-Founder & Group Leader
